RT Journal Article
SR Electronic
T1 Upfront Surgery for Small Intestinal Non-Hodgkin's Lymphoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2373
OP 2377
DO 10.21873/anticanres.14206
VO 40
IS 4
A1 TETSUHIRO IIDA
A1 HIROAKI NOZAWA
A1 HIROFUMI SONODA
A1 KAZUHIRO TOYAMA
A1 KAZUSHIGE KAWAI
A1 KEISUKE HATA
A1 TOSHIAKI TANAKA
A1 TAKESHI NISHIKAWA
A1 KAZUHITO SASAKI
A1 YASUTAKA SHUNO
A1 MANABU KANEKO
A1 KOJI MURONO
A1 SHIGENOBU EMOTO
A1 HIROAKI ISHII
A1 MINEO KUROKAWA
A1 SOICHIRO ISHIHARA
YR 2020
UL http://ar.iiarjournals.org/content/40/4/2373.abstract
AB Background/Aim: The clinical significance of surgery for secondary small intestinal non-Hodgkin's lymphomas (NHL) remains unknown. This study aimed to investigate the efficacy of resection for both primary and secondary small intestinal NHL. Patients and Methods: Twenty patients with small intestinal lymphoma who underwent surgical resection at our Institute between 2009 and 2017 were retrospectively evaluated. The clinicopathological and surgery-related factors were reviewed. We also analyzed their surgical outcomes such as postoperative complications, perforation rate, and overall survival (OS). Results: In total, 13 (65%) and 7 (35%) patients had primary and secondary lymphomas, respectively. A total of 70% of patients were diagnosed with aggressive-type lymphomas. A total of 15 (75%) patients had Lugano system stage IV. Only one (5%) patient experienced postoperative grade II deep vein thrombosis and pulmonary embolism. The 3-year OS rate after surgery was 59.6%. Conclusion: Surgical resection prior to chemotherapy is a feasible and safe therapeutic strategy for small intestinal NHL.